ISRIB Blunts the Integrated Stress Response by Allosterically Antagonising the Inhibitory Effect of Phosphorylated eIF2 on eIF2B.

CRISPR/Cas9-homologous recombination cell stress drug action eukaryotic initiation factor-2B mRNA translation phosphorylation protein binding protein biosynthesis/drug effects protein conformation

Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
07 01 2021
Historique:
received: 30 06 2020
revised: 20 10 2020
accepted: 22 10 2020
pubmed: 22 11 2020
medline: 28 1 2021
entrez: 21 11 2020
Statut: ppublish

Résumé

The small molecule ISRIB antagonizes the activation of the integrated stress response (ISR) by phosphorylated translation initiation factor 2, eIF2(αP). ISRIB and eIF2(αP) bind distinct sites in their common target, eIF2B, a guanine nucleotide exchange factor for eIF2. We have found that ISRIB-mediated acceleration of eIF2B's nucleotide exchange activity in vitro is observed preferentially in the presence of eIF2(αP) and is attenuated by mutations that desensitize eIF2B to the inhibitory effect of eIF2(αP). ISRIB's efficacy as an ISR inhibitor in cells also depends on presence of eIF2(αP). Cryoelectron microscopy (cryo-EM) showed that engagement of both eIF2B regulatory sites by two eIF2(αP) molecules remodels both the ISRIB-binding pocket and the pockets that would engage eIF2α during active nucleotide exchange, thereby discouraging both binding events. In vitro, eIF2(αP) and ISRIB reciprocally opposed each other's binding to eIF2B. These findings point to antagonistic allostery in ISRIB action on eIF2B, culminating in inhibition of the ISR.

Identifiants

pubmed: 33220178
pii: S1097-2765(20)30738-3
doi: 10.1016/j.molcel.2020.10.031
pmc: PMC7837216
pii:
doi:

Substances chimiques

2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide 0
Acetamides 0
Cyclohexylamines 0
Eukaryotic Initiation Factor-2 0
Eukaryotic Initiation Factor-2B 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

88-103.e6

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200848/Z/16/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Références

Nat Commun. 2019 Jun 14;10(1):2640
pubmed: 31201334
EMBO J. 2001 Aug 15;20(16):4349-59
pubmed: 11500362
Elife. 2015 Apr 15;4:e07314
pubmed: 25875391
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Cell Death Dis. 2015 Mar 05;6:e1672
pubmed: 25741597
J Biol Chem. 1987 Oct 25;262(30):14538-43
pubmed: 3667588
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Science. 2019 Nov 15;366(6467):843-849
pubmed: 31727829
PLoS One. 2016 Nov 3;11(11):e0166278
pubmed: 27812215
Nat Methods. 2009 Apr;6(4):275-7
pubmed: 19305406
Mol Biol Cell. 2019 Apr 1;30(8):942-958
pubmed: 30726166
J Biol Chem. 1998 May 22;273(21):12841-5
pubmed: 9582312
Cell. 2015 Oct 22;163(3):712-23
pubmed: 26496610
FASEB J. 1996 Oct;10(12):1378-87
pubmed: 8903508
Proc Natl Acad Sci U S A. 1979 Mar;76(3):1079-83
pubmed: 286294
Mol Cell Biol. 2010 Nov;30(21):5218-33
pubmed: 20805354
J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
Ann Clin Transl Neurol. 2019 Aug;6(8):1407-1422
pubmed: 31402619
Elife. 2017 Apr 27;6:
pubmed: 28447936
EMBO Rep. 2016 Oct;17(10):1374-1395
pubmed: 27629041
Elife. 2018 Feb 28;7:
pubmed: 29489452
Nature. 2016 Mar 3;531(7592):122-5
pubmed: 26901872
Mol Cell. 2003 Mar;11(3):619-33
pubmed: 12667446
Elife. 2019 Jan 09;8:
pubmed: 30624206
Elife. 2013 May 28;2:e00498
pubmed: 23741617
Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2097-2102
pubmed: 30674674
Science. 2019 May 3;364(6439):491-495
pubmed: 31048491
Science. 2015 May 29;348(6238):1027-30
pubmed: 25858979
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6420-E6426
pubmed: 28696288
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Science. 2018 Mar 30;359(6383):1533-1536
pubmed: 29599245
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Elife. 2018 Nov 09;7:
pubmed: 30412051
Nat Commun. 2019 May 13;10(1):2136
pubmed: 31086188
Nucleic Acids Res. 2015 Nov 16;43(20):9994-10014
pubmed: 26384431
Science. 2019 May 3;364(6439):495-499
pubmed: 31048492
J Biol Chem. 2018 May 18;293(20):7766-7776
pubmed: 29618508
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Science. 2018 Mar 30;359(6383):
pubmed: 29599213
Mol Cell Biol. 1997 Mar;17(3):1298-313
pubmed: 9032257

Auteurs

Alisa F Zyryanova (AF)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK.

Kazuhiro Kashiwagi (K)

RIKEN Center for Biosystems Dynamics Research, Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan.

Claudia Rato (C)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK.

Heather P Harding (HP)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK.

Ana Crespillo-Casado (A)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK.

Luke A Perera (LA)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK.

Ayako Sakamoto (A)

RIKEN Center for Biosystems Dynamics Research, Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan.

Madoka Nishimoto (M)

RIKEN Center for Biosystems Dynamics Research, Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan.

Mayumi Yonemochi (M)

RIKEN Center for Biosystems Dynamics Research, Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan.

Mikako Shirouzu (M)

RIKEN Center for Biosystems Dynamics Research, Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan.

Takuhiro Ito (T)

RIKEN Center for Biosystems Dynamics Research, Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan. Electronic address: takuhiro.ito@riken.jp.

David Ron (D)

Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK. Electronic address: dr360@medschl.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH